This IHE publication studies the clinical practice of BOTOX treatment for overactive bladder (OAB). The study was conducted as an anonymised retrospective chart review and included 55 patients suffering from OAB who were treated with BOTOX at two Swedish clinics between 2007 and 2015. The objectives of the study were to:
- assess the resource use of treating OAB patient with BOTOX in real-world clinical practice
- evaluate whether there is external validity of BOTOX treatment (clinical practice vs. clinical trials)
The estimated yearly cost of BOTOX treatment was €902. The patient characteristics in the real-world clinical practice (this study) were similar to those in the clinical trials; with a mean age of 60.2 vs 60.4 and fraction of women of 85 vs 88 percent. This implies a high degree of external validity of clinical trial results.
The results also showed that the treatment intervals were longer in the real world than in clinical trials, indicating that treatment cost could be lower when patients are treated as observed in real-world clinical practice.
Scandinavian Journal of Urology, 2017; 51(5): 397-401